

Shao-Hua Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7846886/publications.pdf>

Version: 2024-02-01

18
papers

475
citations

840776

11
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

526
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study. <i>Liver International</i> , 2021, 41, 378-387.	3.9	35
2	The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE. <i>Aging</i> , 2021, 13, 5358-5368.	3.1	19
3	Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 167-176.	3.7	30
4	Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 959-966.	5.1	15
5	High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. <i>Genes</i> , 2021, 12, 876.	2.4	2
6	Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. <i>Mutagenesis</i> , 2021, 36, 369-379.	2.6	0
7	Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2125055.	5.9	25
8	Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-11.	1.3	5
9	Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study. <i>Frontiers in Oncology</i> , 2020, 10, 573.	2.8	12
10	Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 607.	2.6	33
11	Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. <i>Cancer Medicine</i> , 2020, 9, 2997-3005.	2.8	31
12	NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 369.	6.3	26
13	Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 1430-1437.	0.9	23
14	Prognostic significance of perioperative chemotherapy on resectable colorectal mucinous adenocarcinoma liver metastasis. <i>Annals of Palliative Medicine</i> , 2019, 8, 690-697.	1.2	3
15	Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. <i>Cancer Communications</i> , 2018, 38, 1-12.	9.2	92
16	Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2017, 8, e3043-e3043.	6.3	25
17	Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. <i>Chinese Journal of Cancer</i> , 2017, 36, 83.	4.9	90
18	Identification of Locally Advanced Rectal Cancer with Low Risk of Local Recurrence. <i>PLoS ONE</i> , 2015, 10, e0117141.	2.5	9